DeepMed Research

INSTITUTO GRIFOLS SA

🇪🇸Spain

Country: 🇪🇸Spain

Ownership: Subsidiary

Employees: -

Market Cap: -

Website

Clinical Trials

FIB Grifols Congenital Deficiency for On-demand Treatment and Surgical Prophylaxis

Phase 3

Withdrawn

Conditions: Congenital Afibrinogenemia
Hypofibrinogenemia

Interventions: Biological: FIB Grifols

First Posted Date: 2020-11-19

Last Posted Date: 2023-10-23

Lead Sponsor: Instituto Grifols, S.A.

Registration Number: NCT04636268

A Study to Evaluate Safety and Efficacy of Convalescent Methylene Blue Treated (MBT) Plasma From Donors Recovered From Coronavirus Disease 2019 (COVID-19)

Phase 2

Completed

Conditions: COVID-19

Interventions: Biological: Convalescent anti-SARS-CoV-2 MBT Plasma
Drug: Standard Medical Treatment

First Posted Date: 2020-09-14

Last Posted Date: 2021-03-03

Lead Sponsor: Instituto Grifols, S.A.

Target Recruit Count: 200

Registration Number: NCT04547127

Locations: 🇪🇸
Hospital Universitari de Girona Doctor Josep Trueta, Girona, Spain
🇪🇸
Hospital General Universitario de Alicante, Alicante, Spain
🇪🇸
Hospital Universitari Vall d'Hebron, Barcelona, Spain

and more 9 locations

Study to Evaluate the Safety and Efficacy of Prolastin in Hospitalized Subjects With COVID-19

Phase 2

Completed

Conditions: COVID-19

Interventions: Biological: Prolastin
Drug: Standard Medical Treatment

First Posted Date: 2020-07-31

Last Posted Date: 2021-07-08

Lead Sponsor: Instituto Grifols, S.A.

Target Recruit Count: 100

Registration Number: NCT04495101

Locations: 🇪🇸
Hospital Clínico San Carlos, Madrid, Spain
🇪🇸
Hospital Universitario Príncipe de Asturias, Madrid, Spain
🇪🇸
Hospital Universitario de Burgos, Burgos, Castilla León, Spain

and more 6 locations

Study to Evaluate the Safety and Efficacy of High Dose IVIG in Hospitalized Participants With Coronavirus Disease (COVID-19)

Phase 2

Completed

Conditions: COVID-19

Interventions: Biological: Intravenous Immune Globulin
Drug: Standard Medical Treatment

First Posted Date: 2020-06-16

Last Posted Date: 2021-03-10

Lead Sponsor: Instituto Grifols, S.A.

Target Recruit Count: 100

Registration Number: NCT04432324

Locations: 🇪🇸
Hospital Del Mar, Barcelona, Spain
🇪🇸
Hospital Universitario Infanta Sofía, San Sebastián De Los Reyes, Madrid, Spain
🇪🇸
Hospital Universitari Vall d'Hebron, Barcelona, Spain

and more 7 locations

A Study of Safety and Efficacy of Fibrin Sealant Grifols as an Adjunct to Haemostasis During Surgery in Paediatric Participants

Phase 3

Completed

Conditions: Excessive Bleeding During Surgery

Interventions: Biological: Fibrin Sealant Grifols
Biological: EVICEL

First Posted Date: 2018-03-12

Last Posted Date: 2023-04-14

Lead Sponsor: Instituto Grifols, S.A.

Target Recruit Count: 186

Registration Number: NCT03461406

Locations: 🇧🇬
UMHAT Dr. Georgi Stranski, Pleven, Bulgaria
🇺🇸
The Urological Institute of Northeastern New York, Albany, New York, United States
🇺🇸
St. Christophers Hospital, Philadelphia, Pennsylvania, United States

and more 37 locations

Efficacy and Safety of Plasma Exchange With Albumin in Patients With Amyotrophic Lateral Sclerosis

Phase 2

Completed

Conditions: Amyotrophic Lateral Sclerosis

Interventions: Biological: Albumin

First Posted Date: 2015-06-24

Last Posted Date: 2020-06-16

Lead Sponsor: Instituto Grifols, S.A.

Target Recruit Count: 13

Registration Number: NCT02479802

Locations: 🇪🇸
Hospital Universitari Bellvitge, Hospitalet de Llobregat, Barcelona, Spain

Study of the Efficacy and Safety of Immune Globulin Intravenous (Human) Flebogamma® 5% DIF in Patients With Post-polio Syndrome

Phase 2

Terminated

Conditions: Post-polio Syndrome

Interventions: Biological: Flebogamma 5% DIF
Drug: Placebo

First Posted Date: 2014-06-27

Last Posted Date: 2023-11-27

Lead Sponsor: Instituto Grifols, S.A.

Target Recruit Count: 191

Registration Number: NCT02176863

Locations: 🇩🇰
Aarhus Universitets Hospital-Neurologisk Forskning, Aarhus N, Denmark
🇩🇰
Rigshospitalet, København Ø, Denmark
🇺🇸
Washington University, Saint Louis, Missouri, United States

and more 18 locations

Safety and Efficacy of Topical Thrombin (Human) Grifols as an Adjunct to Hemostasis During Surgery

Phase 2

Completed

Conditions: Hemostasis

Interventions: Biological: Human thrombin
Biological: Bovine thrombin

First Posted Date: 2013-12-18

Last Posted Date: 2017-06-14

Lead Sponsor: Instituto Grifols, S.A.

Target Recruit Count: 181

Registration Number: NCT02014402

Locations: 🇺🇸
602, Los Angeles, California, United States
🇺🇸
908, Hartford, Connecticut, United States
🇺🇸
902, Jackson, Mississippi, United States

and more 17 locations

Safety and Efficacy of Fibrin Sealant Grifols (FS Grifols) During Parenchymous Tissue Open Surgeries

Phase 3

Completed

Conditions: Parenchymous Tissue Surgical Bleeding

Interventions: Device: Surgicel®
Biological: Fibrin Sealant Grifols

First Posted Date: 2012-12-21

Last Posted Date: 2017-02-08

Lead Sponsor: Instituto Grifols, S.A.

Target Recruit Count: 325

Registration Number: NCT01754480

Locations: 🇺🇸
213, New Haven, Connecticut, United States
🇺🇸
206, Nashville, Tennessee, United States
🇷🇺
640, Moscow, Russian Federation

and more 30 locations

Safety and Efficacy Study of Fibrin Sealant Grifols as an Adjunct to Hemostasis During Peripheral Vascular Surgery

Phase 3

Completed

Conditions: Vascular Surgical Bleeding

Interventions: Biological: Fibrin Sealant Grifols
Procedure: Manual Compression

First Posted Date: 2012-08-10

Last Posted Date: 2017-04-06

Lead Sponsor: Instituto Grifols, S.A.

Target Recruit Count: 225

Registration Number: NCT01662856

Locations: 🇺🇸
147, Fort Worth, Texas, United States
🇺🇸
119, San Diego, California, United States
🇺🇸
100, 128, Pittsburgh, Pennsylvania, United States

and more 35 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy